Enterprise Value
1.017B
Cash
330M
Avg Qtr Burn
-24.1M
Short % of Float
21.63%
Insider Ownership
4.17%
Institutional Own.
84.83%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LIVMARLI (Maralixibat) Details Alagille syndrome, Chronic pruritus | Approved Quarterly sales | |
LIVMARLI (Maralixibat) Details Liver disease, Progressive familial intrahepatic cholestasis | PDUFA Approval decision | |
Chenodal® (chenodiol) Details Cerebrotendinous xanthomatosis | NDA Submission | |
Volixibat (VANTAGE) Details Primary biliary cholangitis, Liver disease | Phase 2b Interim update | |
Volixibat (VISTAS) Details Liver disease, Primary sclerosing cholangitis | Phase 2b Interim update | |
LIVMARLI (Maralixibat) Details Rare diseases, Bile duct disease Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
Volixibat (OHANA) Details Liver disease, Intrahepatic Cholestasis of Pregnancy | Failed Discontinued |